In the context of T1D, a bsAb targeting both cytotoxic T-lymphocyte–associated protein-4 (CTLA-4) on T cells and Glucose Transporter Type 2 (GLUT2) on pancreatic β cells has shown potential in preserving β-cell function. Here, SLC2A2 is linked to type 1 diabetes mellitus.